Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor‐α antagonists

摘要: Biologic therapy with tumor necrosis factor (TNF)-alpha antagonists for rheumatoid arthritis has been well established. We describe two patients who developed chronic inflammatory demyelinating polyneuropathy (CIDP) during their course of TNF-alpha antagonists. A 45-year-old woman and a 49-year-old man, both history arthritis, were treated etanercept infliximab, respectively. Clinical signs peripheral neuropathy 2 weeks 12 months after the initiation Electrodiagnostic studies at variable points disease showed acquired demyelination consistent CIDP. Cerebrospinal fluid examination albuminocytologic dissociation (total protein concentration 118 mg/dl 152 mg/dl, respectively). Both failed to improve discontinuation offending agent, they responded poorly corticosteroids. However, there was clinical electrophysiologic recovery intravenous immunoglobulin (IVIg) therapy. CIDP may occur early or late treatment IVIg reverse stabilize process.